ALSO IN THIS MONTH'S ISSUE
-
Strategizing The Scale-Up Of Cell Therapy Manufacturing Capacity
Mike Blankenstein, VP of patient supply operations AT Adaptimmune, discusses the company’s strategy for its cell therapy manufacturing facility and scaling up capacity.
-
A Quick Transition To Late-Stage Clinical Trials
“Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.
-
New DSCSA Compliance Blueprint Includes FDA & Industry Input
As we approach the final phase of a 10-year rollout of the Drug Supply Chain Security Act (DSCSA), which aims to create a more secure, interoperable drug supply chain in the U.S., pharma manufacturers, distributors, and pharmacies must all ensure they are ready for its full implementation starting on Nov. 27, 2023.
-
Key Questions To Ask When Entering A Pharma Partnership
Before entering a partnership, executives need to ask themselves and their prospective partners’ key questions in the following five areas:
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
- 06.06.23 -- Discover The New Possibilities For Increased Dosing Capabilities Offered By Nanoformed APIs
- 06.05.23 -- 8 How To Lead Clinical Research Hybrid Teams
- 06.05.23 -- Overcoming Characterization And Budget Constraints To Address Poor Solubility
- 06.02.23 -- From Biggest Pharma To Rare Disease Start-Up
- 05.31.23 -- 3 Pharmas Try To Solve The Dermatology Puzzle
LIFE SCIENCE LEADER CONTENT COLLECTIONS
ASK THE BOARD
- In Partnering With Academic Institutions To Advance Drug Discovery, What Are The Key Benefits And Challenges?
- In Discussing A Strategic Initiative Presented To The Board By Management, Such As A Bolt-On Acquisition, What Are The Three Core Questions That Boards Should Always Ask?
- In The R&D Space, How Has The Role And Expectations Of A Quality Organization Changed Over Time?